RESEARKA

The clinical-trial landscape for Glycation AGEs-targeted interventions remains nascent and fragmented across several therapeutic domains. The Ozdemir trial in overweight PCOS patients demonstrated that a low-AGE dietary intervention could achieve similar weight loss to a standard-AGE diet while producing favorable shifts in metabolic and hormonal parameters (P = 0.001 for several outcomes), though the intervention's long-term durability and generalizability remain uncertain (Ozdemir 2025). A systematic review of dietary AGE restriction in diabetes populations, encompassing multiple RCTs through February 2024, concluded that the evidence base was heterogeneous in intervention design, AGE quantification method, and clinical endpoints, yielding an overall picture that is suggestive but not definitive (Detopoulou 2024). The Wellens cross-over trial in 20 healthy volunteers demonstrated that cooking methods significantly affect AGE content in foods and downstream lipid profiles, providing proof-of-concept for dietary AGE modulation as a feasible lifestyle intervention (Wellens 2025). Across these trials, the absence of standardized AGE measurement techniques, consensus endpoints, and long-term follow-up designs represents a critical barrier to synthesizing the evidence and informing clinical practice guidelines.

Citation Support

• source_1 Movahedian 2025
• source_2 Kopytek 2025
• source_3 Chang 2025
• source_4 Wu 2025
• source_5 Li 2026